About Paradigm Innomed
Paradigm Innomed is a company based in Noida (India) founded in 2009 by Saumitra Sahai. It operates as a B2B and D2C. Paradigm Innomed offers products and services including Bone Plus, Bonebond, Bonesert, and CART-REP. Paradigm Innomed operates in a competitive market with competitors including Horizon Therapeutics, Osteal Therapeutics, ZetaGen, Angitia and Histogenics, among others.
- Headquarter Noida, India
- Founders Saumitra Sahai
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Paradigm Innomed Llp
- Date of Incorporation 29 Jun, 2016
- Jurisdiction Varanasi, Uttar Pradesh, India
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Paradigm Innomed
Paradigm Innomed offers a comprehensive portfolio of products and services, including Bone Plus, Bonebond, Bonesert, and CART-REP.
Medicine for bone health and repair based on innovative research.
Product for bone repair and enhancement through validated techniques.
Solution for bone-related medical issues and surgical applications.
Product focused on cartilage repair and transformative treatments.
Funding Insights of Paradigm Innomed
Detailed funding history for Paradigm Innomed
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Paradigm Innomed
Investment portfolio details for Paradigm Innomed
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Paradigm Innomed
Detailed financials for Paradigm Innomed
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Paradigm Innomed Comparisons
Peer comparison for Paradigm Innomed
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Paradigm Innomed
Paradigm Innomed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, Osteal Therapeutics, ZetaGen, Angitia and Histogenics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for bone regeneration are developed.
|
|
| Locked | Locked | Locked |
Drugs for muscle, bone, and joint diseases are developed.
|
|
| Locked | Locked | Locked |
Restorative cell therapies for orthopedic diseases are developed.
|
|
| Locked | Locked | Locked |
Advanced cell separation technologies are developed for regenerative cell preparation.
|
Detailed competitors of Paradigm Innomed
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Paradigm Innomed
Complete news archive for Paradigm Innomed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Paradigm Innomed
Paradigm Innomed was founded in 2009.
Paradigm Innomed is headquartered in Noida, India. It is registered at Noida, Uttar Pradesh, India.
Paradigm Innomed is a research-driven company focused on commercializing novel therapeutic products and innovative medical solutions based on contemporary research. It conducts RD collaborations with academic institutions and validates products for serious diseases like bone and cartilage repair. The company operates from Noida, India, with a team of senior scientists ensuring thorough validation before commercialization. Its mission involves bringing new medicines to patients through licensing and development.
Paradigm Innomed's top competitors include Horizon Therapeutics, ZetaGen and Angitia.
Paradigm Innomed offers Bone Plus, Bonebond, Bonesert, and CART-REP.